PHARMACOKINETICS AND PHARMACODYNAMICS OF SARUPLASE, AN UNGLYCOSYLATED SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION

被引:1
|
作者
KOSTER, RW
COHEN, AF
HOPKINS, GR
BEIER, H
GUNZLER, WA
VANDERWOUW, PA
机构
[1] ACAD HOSP LEIDEN,CTR HUMAN DRUG RES,LEIDEN,NETHERLANDS
[2] GRUNENTHAL GMBH,AACHEN,GERMANY
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We examined in patients with acute myocardial infarction (AMI) the pharmacokinetics of saruplase, an unglycosylated, single chain, urokinase-type plasminogen activator (rscu-PA) by measuring urokinase-type plasminogen activator (u-PA) antigen and total u-PA activity, its conversion to active two-chain urokinase-type plasminogen activator (tcu-PA) and evaluated its effect on haemostatic parameters. Twelve patients were studied during and after administration of 20 mg bolus plus 60 mg continuous 1 h i.v. infusion of saruplase. For u-PA antigen and total u-PA activity (expressed as protein equivalents), where 234 U corresponds to 1 mu g, respectively, steady state plasma concentrations were 2.75 +/- 8.3 and 2.50 +/- 7.0 mu g/ml (mean +/- standard deviation) and were reached within 20 min, t(1/2 lambda 1) was 9.1 +/- 1.8 and 7.8 +/- 1.3 min, t(1/2 lambda 2) 1.2 +/- 0.2 and 1.9 +/- 0.5 h, and the total clearance was 393 +/- 110 and 427 +/- 113 ml/min. Inactivation of saruplase in plasma was negligible. After 15 min, tcu-PA was detected in plasma. From the ratio of the areas under the curve of tcu-PA and total u-PA activities it was calculated that 28 +/- 9.3% of the saruplase dose is converted into active Icu-PA. Systemic plasminaemia occurs as shown by a decrease in alpha(2)-antiplasmin and fibrinogen and an increase in fibrinogen degradation products. Thrombin-antithrombin complex formation indicated activation of the clotting system. Saruplase is eliminated rapidly from plasma in AMI patients. A variable, but significant proportion of saruplase is converted into active tcu-PA. At the end of the infusion tcu-PA accounted for 55% of total u-PA activity. Systemic plasmin generation and activation of the clotting system occur during saruplase treatment for AMI.
引用
收藏
页码:740 / 744
页数:5
相关论文
共 50 条
  • [1] THROMBOLYSIS WITH RECOMBINANT UNGLYCOSYLATED SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (SARUPLASE) IN ACUTE MYOCARDIAL-INFARCTION - INFLUENCE OF HEPARIN ON EARLY PATENCY RATE (LIMITS STUDY)
    TEBBE, U
    WINDELER, J
    BOESL, I
    HOFFMANN, H
    WOJCIK, J
    ASHMAWY, M
    SCHWARZ, ER
    VONLOEWIS, P
    ROSEMEYER, P
    HOPKINS, G
    BARTH, H
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (02) : 365 - 373
  • [2] RECOMBINANT SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR DURING ACUTE MYOCARDIAL-INFARCTION
    DIEFENBACH, C
    ERBEL, R
    POP, T
    MATHEY, D
    SCHOFER, J
    HAMM, C
    OSTERMANN, H
    SCHMITZHUBNER, U
    BLEIFELD, W
    MEYER, J
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1988, 61 (13): : 966 - 970
  • [3] INTRAVENOUS THROMBOLYTIC THERAPY WITH SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
    BODE, C
    SCHWARZ, F
    SCHULER, G
    ZIMMERMANN, R
    KUBLER, W
    [J]. THROMBOSIS AND HAEMOSTASIS, 1987, 58 (01) : 209 - 209
  • [4] CORONARY THROMBOLYSIS WITH RECOMBINANT SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
    VANDEWERF, F
    VANHAECKE, J
    DEGEEST, H
    VERSTRAETE, M
    COLLEN, D
    [J]. CIRCULATION, 1986, 74 (05) : 1066 - 1070
  • [5] THROMBOLYTIC THERAPY OF ACUTE MYOCARDIAL-INFARCTION WITH SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR OR PROUROKINASE
    VANDEWERF, F
    [J]. HAEMOSTASIS, 1986, 16 : 33 - 33
  • [6] CORONARY THROMBOLYSIS WITH HUMAN SINGLE-CHAIN, UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (PROUROKINASE) IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
    VANDEWERF, F
    NOBUHARA, M
    COLLEN, D
    [J]. ANNALS OF INTERNAL MEDICINE, 1986, 104 (03) : 345 - 348
  • [7] Hemostatic changes after thrombolytic therapy with saruplase (unglycosylated single-chain urokinase-type plasminogen activator) and urokinase (two-chain urokinase-type plasminogen activator)
    Michels, HR
    Hoffmann, JJML
    Windeler, J
    Hopkins, GR
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (08) : 766 - 771
  • [8] INTRAVENOUS THROMBOLYTIC THERAPY WITH A COMBINATION OF SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND RECOMBINANT TISSUE-TYPE PLASMINOGEN-ACTIVATOR IN ACUTE MYOCARDIAL-INFARCTION
    BODE, C
    SCHULER, G
    NORDT, T
    SCHONERMARK, S
    BAUMANN, H
    RICHARDT, G
    DIETZ, R
    GUREWICH, V
    KUBLER, W
    [J]. CIRCULATION, 1990, 81 (03) : 907 - 913
  • [9] HALF-LIFE OF SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (SCU-PA) AND 2-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (TCU-PA) IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION
    KOHLER, M
    SEN, S
    MIYASHITA, C
    HERMES, R
    PINDUR, G
    HEIDEN, M
    BERG, G
    MORSDORF, S
    LEIPNITZ, G
    ZEPPEZAUER, M
    SCHIEFFER, H
    WENZEL, E
    SCHONBERGER, A
    HOLLEMEYER, K
    [J]. THROMBOSIS RESEARCH, 1991, 62 (1-2) : 75 - 81
  • [10] PHARMACOKINETICS OF SARUPLASE, A RECOMBINANT UNGLYCOSYLATED HUMAN SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR AND ITS EFFECTS ON FIBRINOLYTIC AND HEMOSTATIC PARAMETERS IN HEALTHY MALE-SUBJECTS
    DEBOER, A
    KLUFT, C
    GERLOFF, J
    DOOIJEWAARD, G
    GUNZLER, WA
    BEIER, H
    VANDERMEER, FJM
    COHEN, AF
    [J]. THROMBOSIS AND HAEMOSTASIS, 1993, 70 (02) : 320 - 325